Landscape → Rare Disease

Hemophilia

198 clinical trials

70 active

198 total (since 2015)

Phase 1 Active

62 total

Phase 2 Active

56 total

Phase 3 Active

78 total

Phase 4 Active

37 total

Top Sponsors (Industry)

Sorted by active Active Done Failed

Pfizer 7 13 0

Roche 6 8 1

CSL Behring 4 3 1

Swedish Orphan Biovitrum 4 1 1

Sanofi 3 1 0

Suzhou Alphamab Co., Ltd. 3 1 0

Biocad 3 0 0

Jiangsu Gensciences lnc. 2 5 0

Genzyme, a Sanofi Company 2 4 0

BioMarin Pharmaceutical 2 3 1

Octapharma 2 2 1

Shanghai Xinzhi BioMed Co., Ltd. 2 0 0

Bayer 1 9 2

Bioverativ, a Sanofi company 1 4 0

Equilibra Bioscience LLC 1 0 0

NCT07439055 ACTIVE NOT RECRUITING

Real-World Joint Outcomes After Selective Transition to Low-Dose Emicizumab in Pediatric Hemophilia A

Chulalongkorn University n=18

NCT05568719 RECRUITING

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

Pfizer n=173

NCT07285460 RECRUITING

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

Sanofi n=85

NCT04563520 RECRUITING

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

Emory University n=5

NCT07416604 NOT YET RECRUITING

A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

Hoffmann-La Roche n=360

NCT07416526 NOT YET RECRUITING

A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

Hoffmann-La Roche n=126

NCT07080905 RECRUITING

Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

CSL Behring n=20

NCT05145127 RECRUITING

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

Pfizer n=245

NCT05662319 ACTIVE NOT RECRUITING

A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

Sanofi n=91

NCT04431726 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

Hoffmann-La Roche n=55

NCT06399289 ACTIVE NOT RECRUITING

Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy

CSL Behring n=23

NCT06738485 RECRUITING

Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products

CSL Behring n=60

NCT03754790 ACTIVE NOT RECRUITING

Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX

Genzyme, a Sanofi Company n=281

NCT06003387 RECRUITING

Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

CSL Behring n=35

NCT06833983 RECRUITING

To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A

Gritgen Therapeutics Co., Ltd. n=50

NCT06922045 RECRUITING

Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients

Jiangsu BioJeTay Biotechnology Co., Ltd. n=32

NCT06700096 RECRUITING

An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B

Biocad n=24

NCT05817812 ACTIVE NOT RECRUITING

A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa

Swedish Orphan Biovitrum n=93

NCT03861273 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B

Pfizer n=51

NCT06312475 ACTIVE NOT RECRUITING

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors

Suzhou Alphamab Co., Ltd. n=53

NCT06569108 ACTIVE NOT RECRUITING

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors

Suzhou Alphamab Co., Ltd. n=125

NCT04370054 ACTIVE NOT RECRUITING

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults

Pfizer n=77

NCT05611801 RECRUITING

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

Pfizer n=100

NCT03974113 ACTIVE NOT RECRUITING

Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Genzyme, a Sanofi Company n=32

NCT04644575 ACTIVE NOT RECRUITING

Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A

Bioverativ, a Sanofi company n=261

NCT05203679 ACTIVE NOT RECRUITING

Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug

Shanghai Xinzhi BioMed Co., Ltd. n=32

NCT06938659 NOT YET RECRUITING

Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A Patients

Dhaka Medical College n=20

NCT06738901 NOT YET RECRUITING

An Open-label Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SKP-0141 for the Treatment and Prophylaxis in Severe Hemophilia a Patients

SK Plasma Co., Ltd. n=55

NCT06136507 NOT YET RECRUITING

Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A

Jiangsu Gensciences lnc. n=76

NCT06224907 ACTIVE NOT RECRUITING

Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A

BioMarin Pharmaceutical n=6

NCT06297655 NOT YET RECRUITING

A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. n=60

NCT06155955 RECRUITING

Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A

Chulalongkorn University n=15

NCT06142552 RECRUITING

Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

Jiangsu Gensciences lnc. n=120

NCT04158648 COMPLETED

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors

Hoffmann-La Roche n=73

NCT05147662 COMPLETED

A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood

Bayer n=36

NCT03587116 COMPLETED

A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

Pfizer n=212

NCT04323098 COMPLETED

Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A

BioMarin Pharmaceutical n=22

NCT03315455 COMPLETED

Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants

Hoffmann-La Roche n=85

NCT04759131 COMPLETED

Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A

Bioverativ, a Sanofi company n=74

NCT02615691 COMPLETED

A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

Baxalta now part of Shire n=120

NCT05695391 TERMINATED

A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM

Laboratoire français de Fractionnement et de Biotechnologies n=2

NCT03938792 COMPLETED

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Pfizer n=189

NCT03569891 COMPLETED

HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

CSL Behring n=67

NCT05707351 COMPLETED

A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

Takeda n=37

NCT03370913 COMPLETED

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)

BioMarin Pharmaceutical n=144

NCT06568302 TERMINATED

The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

ApcinteX Ltd n=15

NCT06297486 WITHDRAWN

Study of a Gene Therapy Treatment for Hemophilia A

Spark Therapeutics, Inc.

NCT04580407 COMPLETED

Study of TAK-672 in Participants With Acquired Hemophilia A

Takeda n=5

NCT03855280 COMPLETED

Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B

Medexus Pharma, Inc. n=21

NCT04030052 WITHDRAWN

Emicizumab PUPs and Nuwiq ITI Study

Emory University

NCT04456387 COMPLETED

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

Zhengzhou Gensciences Inc n=119

NCT06137092 COMPLETED

rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study

AryoGen Pharmed Co. n=50

NCT03392974 COMPLETED

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg

BioMarin Pharmaceutical n=1

NCT04845399 COMPLETED

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A

Zhengzhou Gensciences Inc n=101

NCT04303559 TERMINATED

The Hemophilia Inhibitor Prevention Trial

Margaret Ragni n=1

NCT04303572 TERMINATED

The Hemophilia Inhibitor Eradication Trial

Margaret Ragni n=1

NCT02764489 COMPLETED

FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)

Baxalta now part of Shire n=45

NCT03549871 COMPLETED

A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis

Genzyme, a Sanofi Company n=80

NCT03020160 COMPLETED

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A

Hoffmann-La Roche n=48

NCT02847637 COMPLETED

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors

Hoffmann-La Roche n=152

NCT02234323 COMPLETED

An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

Bioverativ, a Sanofi company n=108

NCT03417245 COMPLETED

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

Genzyme, a Sanofi Company n=120

NCT03417102 COMPLETED

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

Genzyme, a Sanofi Company n=60

NCT02548143 COMPLETED

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures

Laboratoire français de Fractionnement et de Biotechnologies n=12

NCT02448680 COMPLETED

A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa

Laboratoire français de Fractionnement et de Biotechnologies n=25

NCT04489537 TERMINATED

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B

Catalyst Biosciences n=18

NCT02895945 TERMINATED

BAX 802 in CHA With Inhibitors

Baxalta now part of Shire n=8

NCT02622321 COMPLETED

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors

Hoffmann-La Roche n=113

NCT03191799 COMPLETED

A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors

Hoffmann-La Roche n=195

NCT02795767 COMPLETED

A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors

Hoffmann-La Roche n=88

NCT02585960 COMPLETED

BAX 855 PK-guided Dosing

Baxalta now part of Shire n=135

NCT03935334 COMPLETED

Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors

AryoGen Pharmed Co. n=48

NCT03376516 COMPLETED

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A

Octapharma n=11

NCT02954575 COMPLETED

Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A

Octapharma n=57

NCT02502149 COMPLETED

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale

Bioverativ Therapeutics Inc. n=24

NCT03815318 COMPLETED

Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A

Sinocelltech Ltd. n=73

NCT02484638 TERMINATED

Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors

CSL Behring n=25

NCT02196207 WITHDRAWN

Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform

Margaret Ragni

NCT07226206 NOT YET RECRUITING

A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

Hoffmann-La Roche

NCT03588299 ACTIVE NOT RECRUITING

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"

Bayer

NCT03307980 ACTIVE NOT RECRUITING

Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B

Pfizer

NCT05987449 RECRUITING

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Hoffmann-La Roche

NCT06379789 RECRUITING

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

Regeneron Pharmaceuticals

NCT05345197 ACTIVE NOT RECRUITING

Emicizumab in Patients With Acquired Hemophilia A

University of Washington

NCT06611436 RECRUITING

BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B

Be Biopharma

NCT06111638 RECRUITING

Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs

Shanghai Xinzhi BioMed Co., Ltd.

NCT04684940 ACTIVE NOT RECRUITING

Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors

BioMarin Pharmaceutical

NCT06120582 RECRUITING

Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)

Biocad

NCT06185335 ACTIVE NOT RECRUITING

A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A

Biocad

NCT03001830 ACTIVE NOT RECRUITING

Gene Therapy for Haemophilia A.

University College, London

NCT05641610 RECRUITING

A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients

Institute of Hematology & Blood Diseases Hospital, China

NCT06747416 NOT YET RECRUITING

KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors

Suzhou Alphamab Co., Ltd.

NCT04676048 RECRUITING

ASC618 Gene Therapy in Hemophilia A Patients

ASC Therapeutics

NCT03061201 COMPLETED

A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A

Pfizer

NCT03370172 COMPLETED

A Study of BAX 888 in Male Adults With Severe Hemophilia A

Baxalta now part of Shire

NCT03520712 TERMINATED

Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5

BioMarin Pharmaceutical

NCT05789524 TERMINATED

The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

ApcinteX Ltd

NCT05789537 TERMINATED

A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors

ApcinteX Ltd

NCT04046848 TERMINATED

Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A

Octapharma

NCT04073498 COMPLETED

The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B)

ApcinteX Ltd

NCT06289166 COMPLETED

Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor

Staidson (Beijing) Biopharmaceuticals Co., Ltd

NCT03003533 COMPLETED

A Gene Transfer Study for Hemophilia A

Spark Therapeutics, Inc.

NCT05421429 COMPLETED

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia

Suzhou Alphamab Co., Ltd.

NCT05027230 COMPLETED

A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Staidson (Beijing) Biopharmaceuticals Co., Ltd

NCT04541628 TERMINATED

Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A

Eli Lilly and Company

NCT06010953 COMPLETED

SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment

Jiangsu Gensciences lnc.

NCT03489291 COMPLETED

Dose Confirmation Trial of AAV5-hFIXco-Padua

CSL Behring

NCT02554773 COMPLETED

An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B

Genzyme, a Sanofi Company

NCT05619926 COMPLETED

Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor

Staidson (Beijing) Biopharmaceuticals Co., Ltd

NCT05164471 TERMINATED

Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B

Spur Therapeutics

NCT03641703 TERMINATED

A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy

Spur Therapeutics

NCT05265286 COMPLETED

A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Jiangsu Gensciences lnc.

NCT04188639 COMPLETED

Emicizumab in Acquired Hemophilia A

GWT-TUD GmbH

NCT03369444 TERMINATED

A Factor IX Gene Therapy Study (FIX-GT)

University College, London

NCT02396342 COMPLETED

Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B

CSL Behring

NCT04394286 TERMINATED

A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects

Baxalta now part of Shire

NCT03205163 COMPLETED

A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)

Bioverativ, a Sanofi company

NCT04548791 TERMINATED

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

Catalyst Biosciences

NCT03095287 TERMINATED

Alphanate in Immune Tolerance Induction Therapy

Grifols Therapeutics LLC

NCT04677803 COMPLETED

BT200 in Hereditary Bleeding Disorders

Medical University of Vienna

NCT03407651 COMPLETED

Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B

Catalyst Biosciences

NCT03995784 COMPLETED

Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B

Catalyst Biosciences

NCT03363321 COMPLETED

PF-06741086 Long-term Treatment in Severe Hemophilia

Pfizer

NCT03597022 TERMINATED

Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors

Bayer

NCT02586012 TERMINATED

Weight-based Dosing in Hemophilia A

Craig Seaman

NCT02484092 COMPLETED

A Gene Therapy Study for Hemophilia B

Pfizer

NCT02974855 COMPLETED

PF-06741086 Multiple Dose Study in Severe Hemophilia

Pfizer

NCT02618915 TERMINATED

Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B

Ultragenyx Pharmaceutical Inc

NCT06579144 RECRUITING

Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A

Swedish Orphan Biovitrum

NCT06349473 RECRUITING

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)

Equilibra Bioscience LLC

NCT03818763 ACTIVE NOT RECRUITING

Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A

Medical College of Wisconsin

NCT06703606 RECRUITING

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

Pfizer

NCT05500807 RECRUITING

Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

Bleeding and Clotting Disorders Institute Peoria, Illinois

NCT05709288 RECRUITING

Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old

Institute of Hematology & Blood Diseases Hospital, China

NCT04418414 NOT YET RECRUITING

Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A

Expression Therapeutics, LLC

NCT05493631 COMPLETED

A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient

GC Biopharma Corp

NCT05042440 COMPLETED

Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A

Sanofi

NCT06025552 COMPLETED

Study of TU7710 in Warfarin Anti-coagulated Healthy Male Subjects

TiumBio Co., Ltd.

NCT04747964 COMPLETED

A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Staidson (Beijing) Biopharmaceuticals Co., Ltd

NCT02695160 TERMINATED

Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B

Sangamo Therapeutics

NCT05265767 COMPLETED

Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A

Christian Medical College, Vellore, India

NCT04864743 COMPLETED

A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Jiangsu Gensciences lnc.

NCT05651061 COMPLETED

A Phase I of SS109 in Hemophilia A or and B With Inhibitors

Jiangsu Gensciences lnc.

NCT05251090 COMPLETED

A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection

Jiangsu Gensciences lnc.

NCT04878731 COMPLETED

Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia

Pfizer

NCT03855696 COMPLETED

A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients

Green Cross Corporation

NCT04072237 COMPLETED

Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia

Catalyst Biosciences

NCT02716194 COMPLETED

BAX 826 Dose-Escalation Safety Study

Baxalta now part of Shire

NCT02418793 COMPLETED

A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B

OPKO Health, Inc.

NCT04015492 COMPLETED

Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII)

Bayer

NCT03186677 COMPLETED

Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients

ISU Abxis Co., Ltd.

NCT03481946 COMPLETED

A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia

Bayer

NCT03996486 WITHDRAWN

Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia

Bayer

NCT02919800 COMPLETED

A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male

OPKO Health, Inc.

NCT03380780 COMPLETED

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers

Hoffmann-La Roche

NCT03364998 COMPLETED

BAY94-9027 PK Study Comparing to Another Long Acting Product

Bayer

NCT02571569 COMPLETED

A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors

Bayer

NCT02506023 COMPLETED

Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers

Emory University

NCT02461992 COMPLETED

Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A

Pfizer

NCT02213250 COMPLETED

An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B

Pfizer

NCT02483208 COMPLETED

Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate

Bayer

NCT07406139 RECRUITING

PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）

Institute of Hematology & Blood Diseases Hospital, China

NCT05181618 ACTIVE NOT RECRUITING

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

Hoffmann-La Roche

NCT05936580 RECRUITING

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

Octapharma

NCT04647227 RECRUITING

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

American Thrombosis and Hemostasis Network

NCT06752850 ACTIVE NOT RECRUITING

A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis

Swedish Orphan Biovitrum

NCT06940830 RECRUITING

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

Swedish Orphan Biovitrum

NCT05935358 RECRUITING

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

Octapharma

NCT06145373 RECRUITING

A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

Sanofi

NCT07158606 NOT YET RECRUITING

Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance Induction

Versiti Blood Health

NCT05849740 RECRUITING

An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A

Institute of Hematology & Blood Diseases Hospital, China

NCT06864975 RECRUITING

Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)

Runhui WU

NCT04690322 RECRUITING

POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies

University of Texas Southwestern Medical Center

NCT05888870 RECRUITING

ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor

Institute of Hematology & Blood Diseases Hospital, China

NCT06320626 RECRUITING

Pharmacokinetic-guided Dosing of Emicizumab

Kathelijn Fischer

NCT04205175 ACTIVE NOT RECRUITING

A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab

Children's Hospital Los Angeles

NCT03384277 COMPLETED

Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab

Institute of Hematology & Blood Diseases Hospital, China

NCT05036278 COMPLETED

Prophylaxis Regimen for Hemophilia A Patients

Bayer

NCT04565236 COMPLETED

A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A

Bayer

NCT05856266 TERMINATED

An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa

Swedish Orphan Biovitrum

NCT03103542 COMPLETED

Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies

Swedish Orphan Biovitrum

NCT04784988 COMPLETED

Intensive Replacement Treatment in Haemophilia Patients With Synovitis

Federico II University

NCT04985682 COMPLETED

A Study of ADVATE in People With Hemophilia A in India

Baxalta now part of Shire

NCT04728217 COMPLETED

Health Related Quality of Life of Youth and Young Adults With Haemophilia A

The League of Clinical Research, Russia

NCT04085458 COMPLETED

Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)

Bayer

NCT05728528 COMPLETED

Impact of Moderate Intensity Physical Activities on PK-guided EHL FVIII Concentrates Prophylaxis Severe HA Patients

Chulalongkorn University

NCT03565237 COMPLETED

RIXUBIS PMS India (RIXUBIS PMS)

Baxalta now part of Shire

NCT05281185 COMPLETED

Clinical Outcomes of Low Dose PK-guided EHL FVIII Concentrates Versus Standard Prophylaxis in Severe Haemophilia A

Chulalongkorn University

NCT04286412 COMPLETED

Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B

Pfizer

NCT03093480 COMPLETED

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

Bioverativ, a Sanofi company

NCT04396639 COMPLETED

Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients

Pfizer

NCT03915080 COMPLETED

Optimizing the Use of Prophylaxis in Patients With Severe Haemophilia A

Lund University

NCT03361137 TERMINATED

Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures

Genentech, Inc.

NCT03204539 TERMINATED

INdividualized ITI Based on Fviii(ATE) Protection by VWF

University of California, Davis

NCT03379974 COMPLETED

Exercise Versus DDAVP in Patients With Mild Hemophilia A

Nationwide Children's Hospital

NCT02336178 COMPLETED

Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China

Pfizer

NCT02492984 COMPLETED

PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A

Pfizer

NCT02727647 COMPLETED

Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients

Chulalongkorn University

Data: ClinicalTrials.gov